Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 8/2014

01-08-2014 | VASCULITIS (LR ESPINOZA, SECTION EDITOR)

Treatment of Severe and/or Refractory ANCA-Associated Vasculitis

Author: Loïc Guillevin

Published in: Current Rheumatology Reports | Issue 8/2014

Login to get access

Abstract

Most patients presenting with systemic necrotizing vasculitides improve when they are adequately treated. The presence of life-threatening manifestations or visceral involvement modifying organ function characterizes severe vasculitis, confirmed by disease-severity scores. Sequelae cannot always be predicted and prevented but organ involvement present at disease onset requires rapid therapeutic intervention. Some patients present a persistent active disease, which does not respond to treatments and deserve other drugs or combination of drugs. The therapeutic options for severe and/or relapsing and refractory diseases are described.
Literature
1.
Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med. 1979;67(6):941–7.PubMedCrossRef
2.
Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979;301(5):235–8.PubMedCrossRef
3.•
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81. The largest series of patients affected with eosinophilic granulomatosis with polyangiitis, describing clinical characteristics, management and outcome.PubMedCrossRef
4.•
Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257–66. This large series of patients with granulomatosis with polyangiitis describes clinical manifestations and outcomes. This paper describes disease evolution over several decades.PubMedCrossRef
5.•
Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26. The largest series of patients with polyarteritis nodosa describing HBV-positive as well as HBV-negative patients, their clinical characteristics and outcomes.PubMedCrossRef
6.••
Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90(1):19–27. This score, when measured at disease onset, predicts prognosis, independently of treatments. It is the first score to predict prognosis of some vasculitides.CrossRef
7.••
Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310–7. These recommendations are a tool for clinicians in charge of patients affected with systemic vasculiites.PubMedCrossRef
8.
Pagnoux C, Quéméneur T, Ninet J, Perrodeau E, Diot E, Kyndt X, et al. Treatment of systemic necrotizing vasculitides in patients ≥65 years old: results of the multicenter randomized CORTAGE trial (Abstract). Presse Med. 2013;42:679–80.CrossRef
9.
Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. Arthritis Rheum. 2010;62(4):1186–97.PubMedCrossRef
10.
Ribi C, Cohen P, Pagnoux C, Mahr A, Arene JP, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58(2):586–94.PubMedCrossRef
11.
Cohen P, Pagnoux C, Mahr A, Arene JP, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57(4):686–93.PubMedCrossRef
12.
Guillevin L, Cohen P, Mahr A, Arene JP, Mouthon L, Puechal X, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93–100.PubMedCrossRef
13.
Le Guenno G, Mahr A, Pagnoux C, Dhote R, Guillevin L. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 2011;63(5):1435–45.PubMedCrossRef
14.•
Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla E, et al. Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibodyassociated necrotizing vasculitides. Presse Med. 2013;42:1317–30. The most recent recommendations to help clinicians to prescribe rituximab in ANCA-associated vasculitis, established by the members of the French Vasculitis Study Group.PubMedCrossRef
15.
Jones R, Harper L, Ballarin J, Blockmans D, Brogan K, Bruchfeld A, et al. A randomized trial of mycophenolate mofetil versus cyclophosphamide for remission induction of ANCA-associated vasculitis: "MYCIC". On behalf of the European Vasculitis Study Group. Presse Med. 2013;42:678. A65.CrossRef
16.
De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9.PubMedCrossRef
17.
Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803.PubMedCrossRef
18.
Rifle G, Dechelette E. Treatment of rapidly progressive glomerulonephritis by plasma exchange and methylprednisolone pulses. A prospective randomized trial of cyclophosphamide. Interim analysis. The French Cooperative Group. Prog Clin Biol Res. 1980;337:263–7.
19.•
Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757–63. This study describes, for the first time, the short-term efficacy of plasma exchanges in patients with severe renal insufficiency and their superiority to pulse methylprednisolone.PubMedCrossRef
20.
Guillevin L, Fain O, Lhote F, Jarrousse B, Le Thi HD, Bussel A, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum. 1992;35(2):208–15.PubMedCrossRef
21.
Guillevin L, Lhote F, Cohen P, Jarrousse B, Lortholary O, Genereau T, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638–45.PubMedCrossRef
22.
Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180–8.PubMedCrossRef
23.
Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41(10):1126–32.CrossRef
24.
Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15(3):717–21.PubMedCrossRef
25.
Josselin L, Mahr A, Cohen P, Pagnoux C, Guaydier-Souquieres G, Hayem G, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis. 2008;67(9):1343–6.PubMedCrossRef
26.
Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351-61.
27.
de Menthon M, Cohen P, Pagnoux C, Buchler M, Sibilia J, Detree F, et al. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S63–71.PubMed
28.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–9.PubMedCrossRef
29.
Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991;337(8750):1137–9.PubMedCrossRef
30.
Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol. 1996;35(11):1150–3.PubMedCrossRef
31.
Richter C, Schnabel A, Csernok E, Reinhold-Keller E, Gross WL. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol. 1993;336:487–9.PubMedCrossRef
32.
Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102(1):c35–42.PubMedCrossRef
33.
Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58(1):308–17.PubMedCrossRef
34.
Langford CA, Monach PA, Specks U, Seo P, Cuthbertson D, McAlear CA, et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis. Online First: December 9, 2013 doi:10.​1136/​annrheumdis-2013-204164.
35.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20.PubMedCrossRef
36.•••
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. The first well-designed prospective trial demonstrating than rituximab is not inferior to cyclophosphamide to induce a remission of ANCA-associated vasculitis.PubMedCentralPubMedCrossRef
37.
Charles P, Néel A, Tieulié N, Hot A, Pugnet G, Decaux O, et al. Rituximab for Induction and Maintenance Treatment of ANCA-Associated Vasculitides. A Multicenter Retrospective Study on 80 Patients. Rheumatology (Oxford). 2014;53:532–9.CrossRef
38.
Charles P, Guillevin L. Rituximab for ANCA-associated vasculitides: the French experience. Presse Med. 2013;42(4 Pt 2):534–6.PubMedCrossRef
39.
Holle JU, Dubrau C, Herlyn K, Heller M, Ambrosch P, Noelle B, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis. 2012;71(3):327–33.PubMedCrossRef
40.
Samson M, Puéchal X, Devilliers H, Ribi C, Cohen P, Bienvenu B, et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without…,. Autoimmun Rev. 2013:on line first: doi. 10.​1016/​j.​autrev.​2013.​10.​001
41.
Samson M, Puechal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–9.PubMedCrossRef
42.
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. Presse Med Q Med Rev. 2013;42:679. Abstract.CrossRef
43.
Hoffman GS. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis? Presse Med. 2013;42(4 Pt 2):643–50.PubMedCrossRef
44.
Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36–44.PubMedCrossRef
45.
de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80.PubMedCrossRef
Metadata
Title
Treatment of Severe and/or Refractory ANCA-Associated Vasculitis
Author
Loïc Guillevin
Publication date
01-08-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 8/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0430-y

Other articles of this Issue 8/2014

Current Rheumatology Reports 8/2014 Go to the issue

Complementary and Alternative Medicine (SL Kolasinski, Section Editor)

Ayurvedic Medicine for Rheumatoid Arthritis

Pediatric Rheumatology (S Ozen, Section Editor)

Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Vaccinations for Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease (KG Saag, Section Editor)

Use of DXA-Based Technology for Detection and Assessment of Risk of Vertebral Fracture in Rheumatology Practice

Spondyloarthritis (MA Khan, Section Editor)

Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits